DelveInsight Blog
Related Article
![](https://assets.delveinsight.com/blog/wp-content/uploads/2016/08/06175101/mergacq_opt.jpg)
Pharma M&A Rebound May Take a While in 2017
The only word that described 2016’s pharma M&A market was “slow.” Some do predict that new year—and administration—could revive energy in the deal making arena, the changes might not happen that fast. The reasons are aplenty, as shares have been sagging under the weight of investor fears of drug-pricing reform. ...
Find More![pharma-news-for-valneva-innovent-gsk-bayer pharma-news-for-valneva-innovent-gsk-bayer](https://assets.delveinsight.com/blog/wp-content/uploads/2024/07/23163511/pharma-news-for-valneva-innovent-gsk-bayer.png)
CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy
CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...
Find More![4-late-stage-iga-nephropathy-treatment-drugs 4-late-stage-iga-nephropathy-treatment-drugs](https://assets.delveinsight.com/blog/wp-content/uploads/2024/07/22160017/4-late-stage-iga-nephropathy-treatment-drugs.png)
4 Late-Stage IgA Nephropathy Treatment Drugs to Look Out
Conventional IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!